Cullinan Therapeutics (Cullinan Therapeutics) Net Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cullinan Therapeutics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. Cullinan Therapeutics's Net Income for the three months ended in Mar. 2024 was $-37.15 Mil. Cullinan Therapeutics's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Cullinan Therapeutics's net margin for the quarter that ended in Mar. 2024 was 0.00%.

The historical rank and industry rank for Cullinan Therapeutics's Net Margin % or its related term are showing as below:

CGEM's Net Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -151.78
* Ranked among companies with meaningful Net Margin % only.

Cullinan Therapeutics Net Margin % Historical Data

The historical data trend for Cullinan Therapeutics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cullinan Therapeutics Net Margin % Chart

Cullinan Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Margin %

Get a 7-Day Free Trial

-346.14

Cullinan Therapeutics Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cullinan Therapeutics's Net Margin %

For the Biotechnology subindustry, Cullinan Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cullinan Therapeutics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cullinan Therapeutics's Net Margin % distribution charts can be found below:

* The bar in red indicates where Cullinan Therapeutics's Net Margin % falls into.

Cullinan Therapeutics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Cullinan Therapeutics's Net Margin for the fiscal year that ended in Dec. 2023 is calculated as

Net Margin	=	Net Income (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-153.162	/	0
	=	%

Cullinan Therapeutics's Net Margin for the quarter that ended in Mar. 2024 is calculated as

Net Margin	=	Net Income (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-37.148	/	0
	=	%

Cullinan Therapeutics (NAS:CGEM) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Cullinan Therapeutics Net Margin % Related Terms

Thank you for viewing the detailed overview of Cullinan Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cullinan Therapeutics (Cullinan Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cullinan Therapeutics Inc (NAS:CGEM) » Definitions » Net Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Main Street, Suite 520, Cambridge, MA, USA, 02142

Website

https://www.cullinanoncology.com

Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.

Executives

Nadim Ahmed	director, officer: President and CEO	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jacquelyn L Sumer	officer: Chief Legal Officer	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jeffrey Alan Jones	officer: Chief Medical Officer	ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Jennifer Michaelson	officer: See Remarks	C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
Jeffrey Trigilio	officer: Chief Financial Officer	C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET, SUTIE 520, CAMBRIDGE MA 02142
David P. Ryan	director	C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Vision Scs F2	10 percent owner	74 GRAND RUE, LUXEMBURG N4 L-1660
Savill Corrine	officer: Acting Chief Business Officer	C/O CULLINAN ONCOLOGY, LLC, ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
F2 Bioscience I 2017 Ltd	10 percent owner	8, RUE SAINT-LEGER, GENEVA V8 CH 1205
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Anne-marie Martin	director	ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Biotechnology Value Fund Ii Lp	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104